
                                SEQUENCE LISTING

<110> National University of Singapore
      Shimasaki, Noriko
      Campana, Dario

<120> Functional Binders Synthesized and
  Secreted by Immune Cells

<130> 4459.1154-001

<150> 62/875,455          
<151> 2019-07-17  

<160> 54

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 48
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Rituximab signal peptide; cDNA

<400> 1
atggacttcc aggtgcagat catcagcttt ctgctgatct ccgcctct              48

<210> 2
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Rituximab signal peptide; amino
      acid

<400> 2
Met Asp Phe Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser
 1               5                  10                  15      


<210> 3
<211> 336
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Immunoglobulin variable domain of
      rituximab light chain; cDNA

<400> 3
gtgatcatgt ccaggggcca gatcgtgctg agccagtccc cagcaatcct gtctgccagc 60
cctggagaga aggtgaccat gacatgccgc gccagctcct ctgtgagcta catccactgg 120
ttccagcaga agcccggcag ctcccctaag ccctggatct atgccacaag caacctggcc 180
tccggcgtgc ctgtgcggtt ttccggctct ggcagcggca cctcctactc tctgacaatc 240
agcagagtgg aggccgagga tgccgccacc tactattgcc agcagtggac ctccaatccc 300
cctacattcg gcggcggcac caagctggag atcaag                           336

<210> 4
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Immunoglobulin variable domain of
      rituximab light chain; amino acid

<400> 4
Val Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
 1               5                  10                  15      
Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
            20                  25                  30          
Ser Ser Val Ser Tyr Ile His Trp Phe Gln Gln Lys Pro Gly Ser Ser
        35                  40                  45              
Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro
    50                  55                  60                  
Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
                85                  90                  95      
Thr Ser Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         


<210> 5
<211> 45
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Linker; cDNA

<400> 5
ggcggcggcg gctctggagg aggaggcagc ggcggaggag gctcc                 45

<210> 6
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Linker; amino acid

<400> 6
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                  10                  15  


<210> 7
<211> 363
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Immunoglobulin variable domain of
      rituximab heavy chain; cDNA

<400> 7
caggtgcagc tgcagcagcc aggagcagag ctggtgaagc caggagcctc tgtgaagatg 60
agctgtaagg cctccggcta caccttcaca agctataaca tgcactgggt gaagcagaca 120
ccaggaaggg gcctggagtg gatcggagca atctaccctg gcaacggcga cacctcctat 180
aatcagaagt ttaagggcaa ggccaccctg acagccgata agtctagctc cacagcctac 240
atgcagctgt ctagcctgac ctctgaggac agcgccgtgt actattgcgc cagaagcaca 300
tactatggcg gcgattggta cttcaacgtg tggggagcag gcaccacagt gaccgtgtct 360
gcc                                                               363

<210> 8
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Immunoglobulin variable domain of
      rituximab heavy chain; amino acid

<400> 8
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30          
Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80  
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
            100                 105                 110         
Ala Gly Thr Thr Val Thr Val Ser Ala
        115                 120     


<210> 9
<211> 699
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Hinge and constant heavy domain 2
      and 3 of immunoglobulin G1; cDNA

<400> 9
gagccaaaga gctgtgacaa gacccacaca tgcccaccat gtccagcacc tgagctgctg 60
ggaggacctt ccgtgttcct gtttcctcca aagccaaagg ataccctgat gatctctagg 120
acccctgagg tgacatgcgt ggtggtggac gtgagccacg aggaccccga ggtgaagttt 180
aactggtacg tggacggcgt ggaggtgcac aatgccaaga ccaagcctcg ggaggagcag 240
tacaactcca catatagagt ggtgtctgtg ctgaccgtgc tgcaccagga ttggctgaac 300
ggcaaggagt ataagtgcaa ggtgtccaat aaggccctgc cagcccccat cgagaagaca 360
atctctaagg ccaagggcca gcctagggag ccacaggtgt acaccctgcc accttcccgc 420
gacgagctga caaagaacca ggtgtctctg acctgtctgg tgaagggctt ctatccatct 480
gacatcgccg tggagtggga gagcaatggc cagcccgaga acaattacaa gaccacacca 540
cccgtgctgg actccgatgg ctctttcttt ctgtatagca agctgacagt ggacaagtcc 600
cggtggcagc agggcaacgt gtttagctgt tccgtgatgc acgaggccct gcacaatcac 660
tacacccaga agtctctgag cctgtccccc ggcaagtga                        699

<210> 10
<211> 232
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL, Hinge and constant heavy domain 2
      and 3 of immunoglobulin G1; amino acid

<400> 10
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 1               5                  10                  15      
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
            20                  25                  30          
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
        35                  40                  45              
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
    50                  55                  60                  
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65                  70                  75                  80  
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
                85                  90                  95      
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
            100                 105                 110         
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
        115                 120                 125             
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
    130                 135                 140                 
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
145                 150                 155                 160 
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
                165                 170                 175     
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
            180                 185                 190         
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
        195                 200                 205             
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
    210                 215                 220                 
Ser Leu Ser Leu Ser Pro Gly Lys
225                 230         


<210> 11
<211> 63
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, CD8alpha signal peptide; cDNA

<400> 11
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
ccg                                                               63

<210> 12
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, CD8alpha signal peptide; amino acid

<400> 12
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1               5                  10                  15      
His Ala Ala Arg Pro
            20      


<210> 13
<211> 321
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Immunoglobulin variable domain of
      light chain; cDNA

<400> 13
gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60
atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca gcagaaacca 120
gatggaactg ttaaactcct gatctaccat acatcaagat tacactcagg agtcccatca 180
aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 240
gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtacac gttcggaggg 300
gggaccaagc tggagatcac a                                           321

<210> 14
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Immunoglobulin variable domain of
      light chain; amino acid

<400> 14
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
        35                  40                  45              
Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65                  70                  75                  80  
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
                85                  90                  95      
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr
            100                 105         


<210> 15
<211> 45
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Linker; cDNA

<400> 15
ggtggcggtg gctcgggcgg tggtgggtcg ggtggcggcg gatct                 45

<210> 16
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Linker; amino acid

<400> 16
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                  10                  15  


<210> 17
<211> 360
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Immunoglobulin variable domain of
      heavy chain; cDNA

<400> 17
gaggtgaaac tgcaggagtc aggacctggc ctggtggcgc cctcacagag cctgtccgtc 60
acatgcactg tctcaggggt ctcattaccc gactatggtg taagctggat tcgccagcct 120
ccacgaaagg gtctggagtg gctgggagta atatggggta gtgaaaccac atactataat 180
tcagctctca aatccagact gaccatcatc aaggacaact ccaagagcca agttttctta 240
aaaatgaaca gtctgcaaac tgatgacaca gccatttact actgtgccaa acattattac 300
tacggtggta gctatgctat ggactactgg ggccaaggaa cctcagtcac cgtctcctca 360


<210> 18
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Immunoglobulin variable domain of
      heavy chain; amino acid

<400> 18
Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
 1               5                  10                  15      
Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr
            20                  25                  30          
Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu
        35                  40                  45              
Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys
    50                  55                  60                  
Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
65                  70                  75                  80  
Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                85                  90                  95      
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln
            100                 105                 110         
Gly Thr Ser Val Thr Val Ser Ser
        115                 120 


<210> 19
<211> 699
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Hinge and constant heavy domain 2
      and 3 of immunoglobulin G1; cDNA

<400> 19
gagccaaaga gctgtgacaa gacccacaca tgcccaccat gtccagcacc tgagctgctg 60
ggaggacctt ccgtgttcct gtttcctcca aagccaaagg ataccctgat gatctctagg 120
acccctgagg tgacatgcgt ggtggtggac gtgagccacg aggaccccga ggtgaagttt 180
aactggtacg tggacggcgt ggaggtgcac aatgccaaga ccaagcctcg ggaggagcag 240
tacaactcca catatagagt ggtgtctgtg ctgaccgtgc tgcaccagga ttggctgaac 300
ggcaaggagt ataagtgcaa ggtgtccaat aaggccctgc cagcccccat cgagaagaca 360
atctctaagg ccaagggcca gcctagggag ccacaggtgt acaccctgcc accttcccgc 420
gacgagctga caaagaacca ggtgtctctg acctgtctgg tgaagggctt ctatccatct 480
gacatcgccg tggagtggga gagcaatggc cagcccgaga acaattacaa gaccacacca 540
cccgtgctgg actccgatgg ctctttcttt ctgtatagca agctgacagt ggacaagtcc 600
cggtggcagc agggcaacgt gtttagctgt tccgtgatgc acgaggccct gcacaatcac 660
tacacccaga agtctctgag cctgtccccc ggcaagtga                        699

<210> 20
<211> 232
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD19 IFL, Hinge and constant heavy domain 2
      and 3 of immunoglobulin G1; amino acid

<400> 20
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 1               5                  10                  15      
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
            20                  25                  30          
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
        35                  40                  45              
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
    50                  55                  60                  
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65                  70                  75                  80  
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
                85                  90                  95      
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
            100                 105                 110         
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
        115                 120                 125             
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
    130                 135                 140                 
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
145                 150                 155                 160 
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
                165                 170                 175     
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
            180                 185                 190         
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
        195                 200                 205             
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
    210                 215                 220                 
Ser Leu Ser Leu Ser Pro Gly Lys
225                 230         


<210> 21
<211> 48
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Rituximab signal
      peptide; cDNA

<400> 21
atggatttcc aggtccagat tatttccttc ctgctgatta gtgccagt              48

<210> 22
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Rituximab signal
      peptide; amino acid

<400> 22
Met Asp Phe Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser
 1               5                  10                  15      


<210> 23
<211> 339
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Immunoglobulin
      variable domain of rituximab light chain; cDNA

<400> 23
gtgattatga gtagaggcca gattgtgctg agccagtccc cagcaatcct gagcgcctcc 60
ccaggagaga aggtgacaat gacctgcaga gccagctcct ctgtgagcta catccactgg 120
ttccagcaga agcccggcag ctccccaaag ccctggatct atgccacctc caacctggcc 180
tctggcgtgc ctgtgagatt ttctggcagc ggctccggca catcttacag cctgaccatc 240
agcagggtgg aggcagagga cgcagcaacc tactattgcc agcagtggac atccaatccc 300
cctaccttcg gcggcggcac aaagctggag atcaagggc                        339

<210> 24
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Immunoglobulin
      variable domain of rituximab light chain; amino
      acid

<400> 24
Val Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
 1               5                  10                  15      
Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
            20                  25                  30          
Ser Ser Val Ser Tyr Ile His Trp Phe Gln Gln Lys Pro Gly Ser Ser
        35                  40                  45              
Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro
    50                  55                  60                  
Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
                85                  90                  95      
Thr Ser Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         


<210> 25
<211> 42
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Linker; cDNA

<400> 25
ggcggcggct ctggaggagg aggaagcgga ggaggaggct cc                    42

<210> 26
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Linker; amino
      acid

<400> 26
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                  10                  15  


<210> 27
<211> 363
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Immunoglobulin
      variable domain of rituximab heavy chain; cDNA

<400> 27
caggtgcagc tgcagcagcc tggagcagag ctggtgaagc caggagccag cgtgaagatg 60
tcctgtaagg cctctggcta cacattcacc agctataaca tgcactgggt gaagcagacc 120
ccaggaagag gcctggagtg gatcggagcc atctaccctg gcaacggcga cacatcctat 180
aatcagaagt ttaagggcaa ggccacactg accgccgata agtctagctc caccgcctac 240
atgcagctgt ctagcctgac atccgaggac tctgccgtgt actattgcgc caggagcacc 300
tactatggcg gcgattggta cttcaacgtg tggggcgccg gcaccacagt gacagtgtct 360
gcc                                                               363

<210> 28
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Immunoglobulin
      variable domain of rituximab heavy chain; amino
      acid

<400> 28
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30          
Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80  
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
            100                 105                 110         
Ala Gly Thr Thr Val Thr Val Ser Ala
        115                 120     


<210> 29
<211> 696
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Hinge and
      constant heavy domain 2 and 3 of immunoglobulin
      G1; cDNA

<400> 29
gagcccaaga gctgtgacaa gacacacacc tgcccaccat gtcctgcacc agagctgctg 60
ggaggaccat ccgtgttcct gtttcctcca aagcccaagg ataccctgat gatctctcgc 120
acacctgagg tgacctgcgt ggtggtggac gtgagccacg aggatccaga ggtgaagttt 180
aactggtacg tggacggcgt ggaggtgcac aatgccaaga ccaagcctag agaggagcag 240
tacaacagca cctatagggt ggtgtccgtg ctgacagtgc tgcaccagga ttggctgaac 300
ggcaaggagt ataagtgcaa ggtgtccaat aaggccctgc ccgcccctat cgagaagacc 360
atctctaagg caaagggaca gccaagggag ccacaggtgt acacactgcc ccctagccgg 420
gacgagctga ccaagaacca ggtgtccctg acatgtctgg tgaagggctt ctatccatcc 480
gatatcgccg tggagtggga gtctaatggc cagcccgaga acaattacaa gaccacacca 540
cccgtgctgg acagcgatgg ctccttcttt ctgtattcta agctgaccgt ggacaagagc 600
cggtggcagc agggcaacgt gttctcctgc tctgtgatgc acgaggccct gcacaatcac 660
tacacccaga agagcctgtc cctgtctccc ggcaag                           696

<210> 30
<211> 232
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, Hinge and
      constant heavy domain 2 and 3 of immunoglobulin
      G1; amino acid

<400> 30
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 1               5                  10                  15      
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
            20                  25                  30          
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
        35                  40                  45              
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
    50                  55                  60                  
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65                  70                  75                  80  
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
                85                  90                  95      
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
            100                 105                 110         
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
        115                 120                 125             
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
    130                 135                 140                 
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
145                 150                 155                 160 
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
                165                 170                 175     
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
            180                 185                 190         
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
        195                 200                 205             
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
    210                 215                 220                 
Ser Leu Ser Leu Ser Pro Gly Lys
225                 230         


<210> 31
<211> 54
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, P2A; cDNA

<400> 31
gccacaaact ttagcctgct gaagcaggca ggcgacgtgg aggagaatcc agga       54

<210> 32
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, P2A; amino acid

<400> 32
Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn
 1               5                  10                  15      
Pro Gly
        


<210> 33
<211> 63
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD8alpha signal
      peptide; cDNA

<400> 33
cccgccctgc cagtgaccgc cctgctgctg cctctggccc tgctgctgca cgcagcccgc 60
cca                                                               63

<210> 34
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD8alpha signal
      peptide; amino acid

<400> 34
Pro Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1               5                  10                  15      
His Ala Ala Arg Pro
            20      


<210> 35
<211> 576
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, FCGR3A
      extracellular domain; cDNA

<400> 35
ggcatgcgga cagaggatct gcccaaggcc gtggtgtttc tggagcctca gtggtaccgc 60
gtgctggaga aggactccgt gaccctgaag tgtcagggcg cctattcccc tgaggataac 120
tctacacagt ggttccacaa tgagtctctg atctcctctc aggccagctc ctactttatc 180
gacgcagcaa ccgtggacga tagcggagag tatcggtgcc agacaaacct gtctaccctg 240
agcgatccag tgcagctgga ggtgcacatc ggatggctgc tgctgcaggc acctagatgg 300
gtgttcaagg aggaggatcc aatccacctg aggtgtcaca gctggaagaa taccgccctg 360
cacaaggtga catacctgca gaacggcaag ggccgcaagt acttccacca caattccgac 420
ttttatatcc caaaggccac cctgaaggat agcggctcct atttttgccg gggcctggtg 480
ggctccaaga acgtgtctag cgagacagtg aatatcacaa tcacccaggg cctggccgtg 540
tctacaatct cctctttctt tcctccaggc taccag                           576

<210> 36
<211> 192
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, FCGR3A
      extracellular domain; amino acid

<400> 36
Gly Met Arg Thr Glu Asp Leu Pro Lys Ala Val Val Phe Leu Glu Pro
 1               5                  10                  15      
Gln Trp Tyr Arg Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gln
            20                  25                  30          
Gly Ala Tyr Ser Pro Glu Asp Asn Ser Thr Gln Trp Phe His Asn Glu
        35                  40                  45              
Ser Leu Ile Ser Ser Gln Ala Ser Ser Tyr Phe Ile Asp Ala Ala Thr
    50                  55                  60                  
Val Asp Asp Ser Gly Glu Tyr Arg Cys Gln Thr Asn Leu Ser Thr Leu
65                  70                  75                  80  
Ser Asp Pro Val Gln Leu Glu Val His Ile Gly Trp Leu Leu Leu Gln
                85                  90                  95      
Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro Ile His Leu Arg Cys
            100                 105                 110         
His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gln Asn
        115                 120                 125             
Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr Ile Pro
    130                 135                 140                 
Lys Ala Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Val
145                 150                 155                 160 
Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn Ile Thr Ile Thr Gln
                165                 170                 175     
Gly Leu Ala Val Ser Thr Ile Ser Ser Phe Phe Pro Pro Gly Tyr Gln
            180                 185                 190         


<210> 37
<211> 207
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD8alpha hinge
      and transmembrane; cDNA

<400> 37
accacaaccc ctgcaccaag accccctaca ccagcaccta ccatcgcaag ccagccactg 60
tccctgcggc ccgaggcctg taggccagca gcaggaggag cagtgcacac caggggcctg 120
gacttcgcct gcgatatcta tatctgggca cctctggcag gaacctgtgg cgtgctgctg 180
ctgagcctgg tcatcaccct gtactgc                                     207

<210> 38
<211> 69
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD8alpha hinge
      and transmembrane; amino acid

<400> 38
Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala
 1               5                  10                  15      
Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly
            20                  25                  30          
Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile
        35                  40                  45              
Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val
    50                  55                  60                  
Ile Thr Leu Tyr Cys
65                  


<210> 39
<211> 126
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD137 cytoplasmic
      domain; cDNA

<400> 39
aagagaggca ggaagaagct gctgtatatc ttcaagcagc cttttatgcg cccagtgcag 60
acaacccagg aggaggacgg ctgctcctgt cggttcccag aagaggagga gggaggatgt 120
gagctg                                                            126

<210> 40
<211> 42
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD137 cytoplasmic
      domain; amino acid

<400> 40
Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
 1               5                  10                  15      
Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
            20                  25                  30          
Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
        35                  40          


<210> 41
<211> 339
<212> DNA
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD3zeta
      cytoplasmic domain; cDNA

<400> 41
agggtgaagt tttctcggag cgccgatgca ccagcatacc agcagggaca gaaccagctg 60
tataacgagc tgaatctggg ccggagagag gagtacgacg tgctggataa gaggcgcggc 120
agggaccccg agatgggagg caagccccgg agaaagaacc ctcaggaggg cctgtacaat 180
gagctgcaga aggacaagat ggccgaggcc tatagcgaga tcggcatgaa gggagagagg 240
cgccggggca agggacacga tggcctgtac cagggcctgt caacagcaac aaaagacact 300
tacgacgcac tgcacatgca ggctctgccc ccaagataa                        339

<210> 42
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> Anti-CD20 IFL-P2A-CD16V-BB-zeta, CD3zeta
      cytoplasmic domain; amino acid

<400> 42
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 1               5                  10                  15      
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
            20                  25                  30          
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
        35                  40                  45              
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
    50                  55                  60                  
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65                  70                  75                  80  
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
                85                  90                  95      
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
            100                 105                 110         


<210> 43
<211> 54
<212> DNA
<213> Artificial Sequence

<220> 
<223> P2A cDNA

<400> 43
gccacaaact ttagcctgct gaagcaggca ggcgacgtgg aggagaatcc agga       54

<210> 44
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> P2A amino acid

<400> 44
Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn
 1               5                  10                  15      
Pro Gly
        


<210> 45
<211> 63
<212> DNA
<213> Artificial Sequence

<220> 
<223> T2A cDNA

<400> 45
ggaagcggag agggcagagg aagtctgcta acatgcggtg acgtcgagga gaatcctgga 60
cct                                                               63

<210> 46
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> T2A amino acid

<400> 46
Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu
 1               5                  10                  15      
Glu Asn Pro Gly Pro
            20      


<210> 47
<211> 69
<212> DNA
<213> Artificial Sequence

<220> 
<223> E2A cDNA

<400> 47
ggaagcggac agtgtactaa ttatgctctc ttgaaattgg ctggagatgt tgagagcaac 60
cctggacct                                                         69

<210> 48
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> E2A amino acid

<400> 48
Gly Ser Gly Gln Cys Thr Asn Tyr Ala Leu Leu Lys Leu Ala Gly Asp
 1               5                  10                  15      
Val Glu Ser Asn Pro Gly Pro
            20              


<210> 49
<211> 75
<212> DNA
<213> Artificial Sequence

<220> 
<223> F2A cDNA

<400> 49
ggaagcggag tgaaacagac tttgaatttt gaccttctca agttggcggg agacgtggag 60
tccaaccctg gacct                                                  75

<210> 50
<211> 25
<212> PRT
<213> Artificial Sequence

<220> 
<223> F2A amino acid

<400> 50
Gly Ser Gly Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala
 1               5                  10                  15      
Gly Asp Val Glu Ser Asn Pro Gly Pro
            20                  25  


<210> 51
<211> 88
<212> DNA
<213> Artificial Sequence

<220> 
<223> Linker of FIG. 8C nucleotide

<400> 51
agctgctgct aaggcactgg aagcagaagc cgcggctaag gaggcggctg caaaagaagc 60
tgcagccaag gaagcagccg cgaaggca                                    88

<210> 52
<211> 46
<212> PRT
<213> Artificial Sequence

<220> 
<223> Linker of FIG. 8C amino acid

<400> 52
Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys
 1               5                  10                  15      
Glu Ala Ala Ala Lys Ala Leu Glu Ala Glu Ala Ala Ala Lys Glu Ala
            20                  25                  30          
Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala
        35                  40                  45      


<210> 53
<211> 342
<212> DNA
<213> Artificial Sequence

<220> 
<223> IL-15 of FIG. 8C nucleotide

<400> 53
aactgggtga atgtgatctc cgacctgaag aagatcgagg atctgatcca gtctatgcac 60
atcgacgcca ccctgtacac agagtccgat gtgcacccct cttgcaaggt gaccgccatg 120
aagtgttttc tgctggagct gcaggtcatc tccctggagt ctggcgacgc cagcatccac 180
gatacagtgg agaacctgat catcctggcc aacaattctc tgtcctctaa cggcaatgtg 240
accgagagcg gctgcaagga gtgtgaggag ctggaggaga agaatatcaa agagttcctg 300
cagagtttcg tccatatcgt ccagatgttt atcaatacct cc                    342

<210> 54
<211> 114
<212> PRT
<213> Artificial Sequence

<220> 
<223> IL-15 of FIG. 8C amino acid

<400> 54
Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile
 1               5                  10                  15      
Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His
            20                  25                  30          
Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln
        35                  40                  45              
Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu
    50                  55                  60                  
Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val
65                  70                  75                  80  
Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile
                85                  90                  95      
Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn
            100                 105                 110         
Thr Ser
        

